Bristol-Myers Squibb (Princeton, NJ) will acquire privately held Adnexus Therapeutics (Waltham, MA), the developer of a new therapeutic class of biologics called Adnectins.
Bristol-Myers Squibb (Princeton, NJ) will acquire privately held Adnexus Therapeutics (Waltham, MA), the developer of a new therapeutic class of biologics called Adnectins. The acquisition of Adnexus will help advance Bristol-Myers Squibb’s biologics strategy across multiple therapeutic areas and includes a Phase 1 oncology biologic, Angiocept. Adnexus Therapeutics will become a subsidiary of Bristol-Myers Squibb and remain based in Waltham, MA.
Under the terms of the agreement, Bristol-Myers Squibb will acquire all of Adnexus’ issued and outstanding shares of capital stock and stock equivalents in an all-cash transaction for a gross purchase price of $430 million. The closing of the transaction is subject to customary regulatory approvals.
Adnectins are a proprietary class of targeted biologics developed by Adnexus. Angiocept is an Adnectin designed to be an anti-angiogenic drug and is currently in Phase 1 development.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.